

Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2026. According to an AGM resolution, the Nomination Committee 2025-2026 should consist of representatives of at least the three largest shareholders and the Chairman of the Board.

Work on composing the Nomination Committee is now completed, and this year's Nomination Committee consists of:

Anders Hallberg, appointed by Hallberg Management AB. Chairman of the Board, Medivir AB
Karl Tobieson, appointed by Linc AB
Johan Claesson, appointed by CA Fastigheter AB and in his own capacity

Karl Tobieson has been appointed Chair of the Nomination Committee.

The 2026 Annual General Meeting of Medivir will be held on Thursday May 7, 2026.

For additional information, please contact;

Magnus Christensen
Chief Financial Officer
Medivir AB
M: +46 8 5468 3100
Email: Magnus.Christensen@medivir.com

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.